Cargando…

Standard Hypercaloric, Hyperproteic vs. Leucine-Enriched Oral Supplements in Patients with Cancer-Induced Sarcopenia, a Randomized Clinical Trial

(1) Background: Malnutrition frequently affects patients with cancer, and it negatively impacts treatment tolerance, clinical outcomes and survival. Thus, appropriate nutritional screening and early nutrition support are extremely recommended. Currently, a significant number of oral supplements (OS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrera-Martínez, Aura D., León Idougourram, Soraya, Muñoz Jiménez, Concepción, Rodríguez-Alonso, Rosa, Alonso Echague, Rosario, Chica Palomino, Sonia, Sanz Sanz, Ana, Manzano García, Gregorio, Gálvez Moreno, María Ángeles, Calañas Continente, Alfonso, Molina Puertas, María José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302788/
https://www.ncbi.nlm.nih.gov/pubmed/37375630
http://dx.doi.org/10.3390/nu15122726
_version_ 1785065125959434240
author Herrera-Martínez, Aura D.
León Idougourram, Soraya
Muñoz Jiménez, Concepción
Rodríguez-Alonso, Rosa
Alonso Echague, Rosario
Chica Palomino, Sonia
Sanz Sanz, Ana
Manzano García, Gregorio
Gálvez Moreno, María Ángeles
Calañas Continente, Alfonso
Molina Puertas, María José
author_facet Herrera-Martínez, Aura D.
León Idougourram, Soraya
Muñoz Jiménez, Concepción
Rodríguez-Alonso, Rosa
Alonso Echague, Rosario
Chica Palomino, Sonia
Sanz Sanz, Ana
Manzano García, Gregorio
Gálvez Moreno, María Ángeles
Calañas Continente, Alfonso
Molina Puertas, María José
author_sort Herrera-Martínez, Aura D.
collection PubMed
description (1) Background: Malnutrition frequently affects patients with cancer, and it negatively impacts treatment tolerance, clinical outcomes and survival. Thus, appropriate nutritional screening and early nutrition support are extremely recommended. Currently, a significant number of oral supplements (OS) are commercially available; despite this, there is a lack of evidence for recommending specific OS, including leucine-enriched OS, for nutritional support in patients with cancer. (2) Aim: To compare the clinical evolution of patients with cancer (undergoing systemic treatment) that received standard hypercaloric, whey protein-based hyperproteic oral supplements vs. hypercaloric, hyperproteic leucine-enriched OS using a novel morphofunctional nutritional evaluation. (3) Patients and methods: This paper details an open-label, controlled clinical study in which patients were randomly assigned to receive nutritional treatment with whey protein-based hyperproteic oral supplements (control group) vs. hypercaloric, hyperproteic leucine-enriched OS (intervention group) during a twelve-week period. Forty-six patients were included; epidemiological, clinical, anthropometric, ultrasound (muscle echography of the rectus femoris muscle of the quadriceps and abdominal adipose tissue) and biochemical evaluation were performed. All patients received additional supplementation with vitamin D. (4) Results: Nutritional parameters (including bioimpedance, anthropometric, ultrasound and biochemical variables) of all included patients remained stable after the nutritional intervention. Extracellular mass tended to increase in the patients that received the leucine-enriched formula. Functionality (evaluated through the stand-up test) improved in both groups (p < 0.001). Prealbumin, transferrin levels and superficial adipose tissue increased in the control group (p < 0.05), while self-reported quality of life improved in all the evaluated patients (p < 0.001). (5) Conclusions: Nutritional support with hypercaloric, hyperproteic (with whey protein) OS and vitamin D supplementation were associated with the maintenance of body composition and improvements in functionality and in quality of life in the patients with cancer undergoing systemic treatment. No significant benefits were observed when a leucine-enriched formula was used.
format Online
Article
Text
id pubmed-10302788
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103027882023-06-29 Standard Hypercaloric, Hyperproteic vs. Leucine-Enriched Oral Supplements in Patients with Cancer-Induced Sarcopenia, a Randomized Clinical Trial Herrera-Martínez, Aura D. León Idougourram, Soraya Muñoz Jiménez, Concepción Rodríguez-Alonso, Rosa Alonso Echague, Rosario Chica Palomino, Sonia Sanz Sanz, Ana Manzano García, Gregorio Gálvez Moreno, María Ángeles Calañas Continente, Alfonso Molina Puertas, María José Nutrients Article (1) Background: Malnutrition frequently affects patients with cancer, and it negatively impacts treatment tolerance, clinical outcomes and survival. Thus, appropriate nutritional screening and early nutrition support are extremely recommended. Currently, a significant number of oral supplements (OS) are commercially available; despite this, there is a lack of evidence for recommending specific OS, including leucine-enriched OS, for nutritional support in patients with cancer. (2) Aim: To compare the clinical evolution of patients with cancer (undergoing systemic treatment) that received standard hypercaloric, whey protein-based hyperproteic oral supplements vs. hypercaloric, hyperproteic leucine-enriched OS using a novel morphofunctional nutritional evaluation. (3) Patients and methods: This paper details an open-label, controlled clinical study in which patients were randomly assigned to receive nutritional treatment with whey protein-based hyperproteic oral supplements (control group) vs. hypercaloric, hyperproteic leucine-enriched OS (intervention group) during a twelve-week period. Forty-six patients were included; epidemiological, clinical, anthropometric, ultrasound (muscle echography of the rectus femoris muscle of the quadriceps and abdominal adipose tissue) and biochemical evaluation were performed. All patients received additional supplementation with vitamin D. (4) Results: Nutritional parameters (including bioimpedance, anthropometric, ultrasound and biochemical variables) of all included patients remained stable after the nutritional intervention. Extracellular mass tended to increase in the patients that received the leucine-enriched formula. Functionality (evaluated through the stand-up test) improved in both groups (p < 0.001). Prealbumin, transferrin levels and superficial adipose tissue increased in the control group (p < 0.05), while self-reported quality of life improved in all the evaluated patients (p < 0.001). (5) Conclusions: Nutritional support with hypercaloric, hyperproteic (with whey protein) OS and vitamin D supplementation were associated with the maintenance of body composition and improvements in functionality and in quality of life in the patients with cancer undergoing systemic treatment. No significant benefits were observed when a leucine-enriched formula was used. MDPI 2023-06-12 /pmc/articles/PMC10302788/ /pubmed/37375630 http://dx.doi.org/10.3390/nu15122726 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Herrera-Martínez, Aura D.
León Idougourram, Soraya
Muñoz Jiménez, Concepción
Rodríguez-Alonso, Rosa
Alonso Echague, Rosario
Chica Palomino, Sonia
Sanz Sanz, Ana
Manzano García, Gregorio
Gálvez Moreno, María Ángeles
Calañas Continente, Alfonso
Molina Puertas, María José
Standard Hypercaloric, Hyperproteic vs. Leucine-Enriched Oral Supplements in Patients with Cancer-Induced Sarcopenia, a Randomized Clinical Trial
title Standard Hypercaloric, Hyperproteic vs. Leucine-Enriched Oral Supplements in Patients with Cancer-Induced Sarcopenia, a Randomized Clinical Trial
title_full Standard Hypercaloric, Hyperproteic vs. Leucine-Enriched Oral Supplements in Patients with Cancer-Induced Sarcopenia, a Randomized Clinical Trial
title_fullStr Standard Hypercaloric, Hyperproteic vs. Leucine-Enriched Oral Supplements in Patients with Cancer-Induced Sarcopenia, a Randomized Clinical Trial
title_full_unstemmed Standard Hypercaloric, Hyperproteic vs. Leucine-Enriched Oral Supplements in Patients with Cancer-Induced Sarcopenia, a Randomized Clinical Trial
title_short Standard Hypercaloric, Hyperproteic vs. Leucine-Enriched Oral Supplements in Patients with Cancer-Induced Sarcopenia, a Randomized Clinical Trial
title_sort standard hypercaloric, hyperproteic vs. leucine-enriched oral supplements in patients with cancer-induced sarcopenia, a randomized clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302788/
https://www.ncbi.nlm.nih.gov/pubmed/37375630
http://dx.doi.org/10.3390/nu15122726
work_keys_str_mv AT herreramartinezaurad standardhypercalorichyperproteicvsleucineenrichedoralsupplementsinpatientswithcancerinducedsarcopeniaarandomizedclinicaltrial
AT leonidougourramsoraya standardhypercalorichyperproteicvsleucineenrichedoralsupplementsinpatientswithcancerinducedsarcopeniaarandomizedclinicaltrial
AT munozjimenezconcepcion standardhypercalorichyperproteicvsleucineenrichedoralsupplementsinpatientswithcancerinducedsarcopeniaarandomizedclinicaltrial
AT rodriguezalonsorosa standardhypercalorichyperproteicvsleucineenrichedoralsupplementsinpatientswithcancerinducedsarcopeniaarandomizedclinicaltrial
AT alonsoechaguerosario standardhypercalorichyperproteicvsleucineenrichedoralsupplementsinpatientswithcancerinducedsarcopeniaarandomizedclinicaltrial
AT chicapalominosonia standardhypercalorichyperproteicvsleucineenrichedoralsupplementsinpatientswithcancerinducedsarcopeniaarandomizedclinicaltrial
AT sanzsanzana standardhypercalorichyperproteicvsleucineenrichedoralsupplementsinpatientswithcancerinducedsarcopeniaarandomizedclinicaltrial
AT manzanogarciagregorio standardhypercalorichyperproteicvsleucineenrichedoralsupplementsinpatientswithcancerinducedsarcopeniaarandomizedclinicaltrial
AT galvezmorenomariaangeles standardhypercalorichyperproteicvsleucineenrichedoralsupplementsinpatientswithcancerinducedsarcopeniaarandomizedclinicaltrial
AT calanascontinentealfonso standardhypercalorichyperproteicvsleucineenrichedoralsupplementsinpatientswithcancerinducedsarcopeniaarandomizedclinicaltrial
AT molinapuertasmariajose standardhypercalorichyperproteicvsleucineenrichedoralsupplementsinpatientswithcancerinducedsarcopeniaarandomizedclinicaltrial